Q1 Earnings Forecast for MediWound Issued By HC Wainwright

MediWound Ltd. (NASDAQ:MDWD - Free Report) - Analysts at HC Wainwright cut their Q1 2025 earnings estimates for shares of MediWound in a research report issued on Thursday, March 20th. HC Wainwright analyst S. Ramakanth now anticipates that the biopharmaceutical company will post earnings per share of ($0.61) for the quarter, down from their prior estimate of ($0.56). HC Wainwright has a "Buy" rating and a $25.00 price target on the stock. The consensus estimate for MediWound's current full-year earnings is ($2.66) per share. HC Wainwright also issued estimates for MediWound's Q2 2025 earnings at ($0.66) EPS, Q4 2025 earnings at ($0.73) EPS, FY2025 earnings at ($2.71) EPS, FY2026 earnings at ($1.98) EPS, FY2027 earnings at ($1.16) EPS and FY2028 earnings at $0.80 EPS.

MediWound (NASDAQ:MDWD - Get Free Report) last released its quarterly earnings results on Wednesday, March 19th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.59) by $0.23. The firm had revenue of $5.84 million during the quarter, compared to the consensus estimate of $5.79 million. MediWound had a negative net margin of 142.29% and a negative return on equity of 82.17%. During the same quarter in the prior year, the firm earned ($0.19) EPS.

MDWD has been the topic of a number of other reports. Craig Hallum initiated coverage on MediWound in a research report on Friday, February 28th. They set a "buy" rating and a $39.00 price target for the company. StockNews.com raised shares of MediWound to a "sell" rating in a research note on Friday, March 21st.

Remove Ads

MediWound Trading Up 2.7 %

NASDAQ:MDWD traded up $0.45 during trading hours on Monday, hitting $16.98. 103,164 shares of the stock were exchanged, compared to its average volume of 89,400. The firm's fifty day moving average price is $18.03 and its 200 day moving average price is $17.58. MediWound has a 52-week low of $12.78 and a 52-week high of $24.00. The company has a market cap of $183.27 million, a P/E ratio of -5.86 and a beta of 0.82.

Institutional Investors Weigh In On MediWound

A number of large investors have recently made changes to their positions in the stock. State Street Corp increased its holdings in shares of MediWound by 219.6% during the 3rd quarter. State Street Corp now owns 66,258 shares of the biopharmaceutical company's stock worth $1,197,000 after buying an additional 45,529 shares during the last quarter. Barclays PLC raised its position in MediWound by 311.3% in the third quarter. Barclays PLC now owns 11,163 shares of the biopharmaceutical company's stock valued at $202,000 after purchasing an additional 8,449 shares during the period. Rhumbline Advisers lifted its stake in shares of MediWound by 7.3% in the 4th quarter. Rhumbline Advisers now owns 10,835 shares of the biopharmaceutical company's stock valued at $193,000 after purchasing an additional 739 shares during the last quarter. Point72 Asset Management L.P. acquired a new position in shares of MediWound in the 3rd quarter valued at $212,000. Finally, Essex Investment Management Co. LLC grew its holdings in shares of MediWound by 30.7% during the 4th quarter. Essex Investment Management Co. LLC now owns 148,949 shares of the biopharmaceutical company's stock worth $2,651,000 after purchasing an additional 35,012 shares during the period. 46.83% of the stock is currently owned by hedge funds and other institutional investors.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.